Bioventus heads into its third-quarter report with two stories running side by side. One is a potential sale of the company, after an unsolicited acquisition proposal and several other expressions of interest prompted the board to form an independent committee and hire Qatalyst to weigh its options. The other is more mundane but arguably more important: whether the top-line softness of the second quarter was the timing blip management described or the start of something more stubborn. The numbers due after the close on November 2 will speak directly to the second question, and the answer could shape how much a buyer is willing to pay.
The Street expects adjusted earnings of $0.17 per share on revenue of $149.5 million, up about 13% and 8% respectively from a year ago. That revenue growth rate matters. Second-quarter sales rose only 4%, down from 7% in the first quarter and high single digits organically in late 2025. Management reaffirmed full-year guidance of $600 million to $610 million in revenue and $0.75 to $0.79 in adjusted EPS, and said second-half growth should improve by more than 300 basis points, roughly half from orders that slipped out of the second quarter and half from the ramp in its PRP and peripheral nerve stimulation products. Consensus revenue of $605.3 million sits squarely in the middle of the range, but the $0.79 EPS estimate is pinned at the top, which leaves little cushion if margins or the higher tax rate disappoint.
Pain treatments are the part of the story that needs the least defending. Hyaluronic acid injections, led by double-digit Durolane volume growth, rose 12% last quarter and remain the company's growth engine. A healthy result here, along with evidence that the two-way selling relationship between the HA and PRP sales efforts is producing new accounts in both directions, would support management's view that its newer products are building on a durable base. The PRP and nerve stimulation lines are still expected to add about 200 basis points to full-year growth, so capital placements and reorder trends should start showing up in reported revenue rather than only in leading indicators.
The tougher test lies elsewhere. Surgical, restorative and international sales all declined year over year in the second quarter, the first time three of the four segments turned negative together. About $2 million of ultrasonics and international distributor orders were pushed into the back half, which management said dragged surgical growth by nearly 400 basis points. If those dollars show up now, surgical and international should rebound visibly. Restorative is a harder call, since the Exogen decline was tied to an unfavorable Medicare mix rather than timing, and continued weakness would suggest a structural headwind. Gross margin, which slipped 90 basis points to 75% on freight and mix, is the other swing factor given how tightly the EPS estimate hugs the top of guidance.
The market has already leaned toward the optimistic reading. Shares have climbed 16% since the last report while the S&P 500 slipped 1.4%, and at $14.72 the stock trades well above its 200-day moving average of $10.76, though still about 7% below its post-earnings high of $15.89. Sentiment has swung from mildly bearish before the prior report to modestly bullish now. Much of that lift likely reflects takeover optionality, which can cushion the stock but also raises the bar for the underlying business.
Ultimately, this quarter is about credibility. If revenue growth reaccelerates toward 8% with surgical and international recovering as promised, the second-quarter dip will look like the timing issue management claimed, and the case for both standalone value and a sale price strengthens. If the snap-back is partial, top-of-range EPS hopes and the reaffirmed outlook will face harder questions, strategic review or not.